Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRUCE RANKIN

Allopathic & Osteopathic Physicians Family Medicine

NPI
1922027853
CMS profile
132925
Location
DELAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$6,373.98

97 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $3,980.38 13
Food and Beverage $2,387.60 83
Education $6.00 1

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 97 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRUCE RANKIN

NPI 1922027853 · CMS profile ID 132925

Allopathic & Osteopathic Physicians / Family Medicine

DELAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 97 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1922027853?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 97 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922027853?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 97 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922027853?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 97 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1922027853?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

97 matching records · $6,373.98 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 97 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 97.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $14.0012/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673828509 CMS
Ultragenyx Pharmaceutical Inc. $16.1512/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703130877 CMS
GlaxoSmithKline, LLC. $11.6512/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671435733 CMS
AstraZeneca Pharmaceuticals LP $12.0811/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685611263 CMS
AstraZeneca Pharmaceuticals LP $13.7511/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685974777 CMS
Novo Nordisk Inc $19.7011/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674649529 CMS
Astellas Pharma US Inc $19.4811/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655737003 CMS
AstraZeneca Pharmaceuticals LP $12.6911/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685469465 CMS
Allergan Inc. $19.3011/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670990317 CMS
Allergan Inc. $17.9211/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701305917 CMS
AstraZeneca Pharmaceuticals LP $13.6410/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685090245 CMS
PFIZER INC. $13.1510/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673176687 CMS
GlaxoSmithKline, LLC. $11.4710/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671488733 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.0610/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700170735 CMS
Lilly USA, LLC $15.4910/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657713505 CMS
Teva Pharmaceuticals USA, Inc. $11.8110/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697773845 CMS
AstraZeneca Pharmaceuticals LP $13.5910/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685325041 CMS
Lilly USA, LLC $11.9410/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657727481 CMS
Lilly USA, LLC $14.9009/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657713503 CMS
AstraZeneca Pharmaceuticals LP $12.2009/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685537981 CMS
SANOFI-AVENTIS U.S. LLC $20.2809/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694130609 CMS
Amgen Inc. $13.0209/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662228141 CMS
Teva Pharmaceuticals USA, Inc. $18.2409/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697731571 CMS
PFIZER INC. $12.3708/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672526481 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.2008/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700170737 CMS
AstraZeneca Pharmaceuticals LP $16.5708/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685251551 CMS
AstraZeneca Pharmaceuticals LP $15.9207/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685288547 CMS
Allergan Inc. $13.9107/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670990309 CMS
AstraZeneca Pharmaceuticals LP $12.5207/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685857727 CMS
Amgen Inc. $16.0507/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662228139 CMS
PFIZER INC. $596.0107/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672596863 CMS
Merck Sharp & Dohme Corporation $5.7607/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695633539 CMS
GlaxoSmithKline, LLC. $13.9107/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671380680 CMS
Merck Sharp & Dohme Corporation $12.2107/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695618271 CMS
AstraZeneca Pharmaceuticals LP $19.1206/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685280647 CMS
AstraZeneca Pharmaceuticals LP $12.6906/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685200601 CMS
PFIZER INC. $15.9806/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672148949 CMS
Novo Nordisk Inc $23.5806/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674432943 CMS
Merck Sharp & Dohme Corporation $9.4906/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695556737 CMS
Teva Pharmaceuticals USA, Inc. $12.7106/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697713715 CMS
Novo Nordisk Inc $16.2406/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674432945 CMS
PFIZER INC. $15.2006/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672229199 CMS
PFIZER INC. $204.8606/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672260617 CMS
PFIZER INC. $271.1306/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672260619 CMS
Astellas Pharma US Inc $17.1206/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655737001 CMS
PFIZER INC. $14.9106/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672198613 CMS
Merck Sharp & Dohme Corporation $29.7705/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804329 CMS
Merck Sharp & Dohme Corporation $49.9805/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804331 CMS
Merck Sharp & Dohme Corporation $50.0005/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804333 CMS
Merck Sharp & Dohme Corporation $78.4105/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804335 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,373.98 97
PY2020 $739.07 44
PY2021 $406.88 25
PY2022 $30.36 2
PY2023 $3,057.34 11
PY2024 $1,612.22 12
PY2025 $249.99 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,755.45 1
PY2025 Principal investigator $4,230,288.19 209
PY2024 Recipient $1,330.16 13
PY2024 Principal investigator $3,187,354.20 327
PY2023 Recipient $893.27 4
PY2023 Principal investigator $6,323,793.75 2,767
PY2022 Recipient $462.00 2
PY2022 Principal investigator $6,941,300.42 589
PY2021 Recipient $15.00 1
PY2021 Principal investigator $10,036,876.19 348
PY2020 Recipient $10,602.17 4
PY2020 Principal investigator $3,545,507.10 644
PY2019 Principal investigator $2,410,610.06 875

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

591 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $53,434.59 12/31/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age No dispute reported 06/30/2026 940395355
Principal investigator 1 Merck Sharp & Dohme LLC $1,055.60 12/31/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age No dispute reported 06/30/2026 940395359
Principal investigator 1 Janssen Pharmaceuticals, Inc $16,969.00 12/27/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214979
Principal investigator 1 Janssen Research & Development, LLC $139.00 12/27/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221283
Principal investigator 1 Novo Nordisk AS $54.00 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 896867613
Principal investigator 1 Novo Nordisk AS $40.29 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 896867617
Principal investigator 1 Novo Nordisk AS $3.94 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 896867621
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 896867747
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 896867763
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 896867803
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 896867807
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 896867811
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 896946701
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 896946705
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 896946709
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 896946713
Principal investigator 1 Novo Nordisk AS $30.78 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 896946715
Principal investigator 1 Novo Nordisk AS $30.78 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 896946719
Principal investigator 1 Novo Nordisk AS $3.94 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 896946723
Principal investigator 1 Novo Nordisk AS $3.90 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 896949113
Principal investigator 1 Novo Nordisk AS $3.90 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 896949501
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 896949553
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 896949557
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897008945
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897009091
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897009093
Principal investigator 1 Novo Nordisk AS $40.29 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897009099
Principal investigator 1 Novo Nordisk AS $40.29 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897009103
Principal investigator 1 Novo Nordisk AS $40.29 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897009107
Principal investigator 1 Novo Nordisk AS $40.29 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897009110
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897011881
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897011885
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897011889
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897011893
Principal investigator 1 Novo Nordisk AS $3.94 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897011897
Principal investigator 1 Novo Nordisk AS $40.29 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897028829
Principal investigator 1 Novo Nordisk AS $30.78 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897028834
Principal investigator 1 Novo Nordisk AS $3.94 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897028839
Principal investigator 1 Novo Nordisk AS $3.90 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897028843
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897029655
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897030535
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897030539
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897030685
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897038585
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897038589
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897038593
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897038665
Principal investigator 1 Novo Nordisk AS $90.00 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897038669
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897043025
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897043029
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897043033
Principal investigator 1 Novo Nordisk AS $40.29 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897043037
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897044293
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897044343
Principal investigator 1 Novo Nordisk AS $8.55 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897073123
Principal investigator 1 Novo Nordisk AS $3.90 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897077461
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897077465
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897114305
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897114309
Principal investigator 1 Novo Nordisk AS $30.78 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897115151
Principal investigator 1 Novo Nordisk AS $3.94 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897115153
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897115197
Principal investigator 1 Novo Nordisk AS $3.70 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897146545
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897146551
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897146553
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897146559
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897146563
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897146567
Principal investigator 1 Novo Nordisk AS $3.90 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897149619
Principal investigator 1 Novo Nordisk AS $3.70 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897149623
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897149627
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897149631
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897149635
Principal investigator 1 Novo Nordisk AS $3.90 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897196963
Principal investigator 1 Novo Nordisk AS $3.90 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897196967
Principal investigator 1 Novo Nordisk AS $3.70 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897196971
Principal investigator 1 Novo Nordisk AS $3.70 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897197047
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897197051
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897197055
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897197059
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897197063
Principal investigator 1 Novo Nordisk AS $3.94 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897197067
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897197075
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897197187
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897198143
Principal investigator 1 Novo Nordisk AS $30.78 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897198147
Principal investigator 1 Novo Nordisk AS $13.50 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897198151
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897198155
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897198159
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897210171
Principal investigator 1 Novo Nordisk AS $3.90 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897210339
Principal investigator 1 Novo Nordisk AS $3.70 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897210344
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897210349
Principal investigator 1 Novo Nordisk AS $3.05 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897210355
Principal investigator 1 Novo Nordisk AS $30.78 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897210360
Principal investigator 1 Novo Nordisk AS $13.50 12/27/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 897210363
Principal investigator 1 Janssen Research & Development, LLC $1,797.50 12/26/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885248079
Principal investigator 1 ModernaTX, Inc. $49,681.35 12/23/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260177
Principal investigator 1 ModernaTX, Inc. $54,529.20 12/23/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260183
Principal investigator 1 ModernaTX, Inc. $51,139.35 12/23/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260189
Principal investigator 1 ModernaTX, Inc. $52,998.30 12/23/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260195
Principal investigator 1 ModernaTX, Inc. $50,920.65 12/23/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260201
Principal investigator 1 ModernaTX, Inc. $2,405.70 12/23/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260207
Principal investigator 1 ModernaTX, Inc. $28,437.75 12/23/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260213
Principal investigator 1 ModernaTX, Inc. $27,546.75 12/23/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260219
Principal investigator 1 ModernaTX, Inc. $27,324.00 12/23/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260225
Principal investigator 1 ModernaTX, Inc. $26,730.00 12/23/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260231
Principal investigator 1 ModernaTX, Inc. $26,358.75 12/23/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260237
Principal investigator 1 ModernaTX, Inc. $25,839.00 12/23/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260243
Principal investigator 1 ModernaTX, Inc. $19,824.75 12/23/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260249
Principal investigator 1 ModernaTX, Inc. $2,747.25 12/23/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260255
Principal investigator 1 ModernaTX, Inc. $49,243.95 12/23/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260259
Principal investigator 1 ModernaTX, Inc. $23,838.30 12/23/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260265
Principal investigator 1 ModernaTX, Inc. $24,873.75 12/23/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260271
Principal investigator 1 ModernaTX, Inc. $36.45 12/23/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260277
Principal investigator 1 ModernaTX, Inc. $50,228.10 12/23/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260283
Principal investigator 1 PFIZER INC. $4,876.89 12/22/2022 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949774663
Principal investigator 1 Janssen Research & Development, LLC $200.00 12/19/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 885221335
Principal investigator 1 Janssen Research & Development, LLC $250.00 12/19/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65Years No dispute reported 06/30/2026 885248041
Principal investigator 1 Janssen Pharmaceuticals, Inc $90.00 12/16/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214983
Principal investigator 1 Janssen Research & Development, LLC $139.00 12/16/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221291
Principal investigator 1 Janssen Research & Development, LLC $4,435.00 12/16/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 885221343
Principal investigator 1 Eli Lilly and Company $1,208.00 12/15/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3857210 FOR THE TREATMENT OF CHRONIC LOW BACK PAIN No dispute reported 06/30/2026 917845907
Principal investigator 1 Janssen Research & Development, LLC $30.00 12/15/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65Years No dispute reported 06/30/2026 885248043
Principal investigator 1 ModernaTX, Inc. $1,751.90 12/15/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260171
Principal investigator 1 ModernaTX, Inc. $32,393.25 12/15/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260325
Principal investigator 1 ModernaTX, Inc. $48,689.10 12/15/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260331
Principal investigator 1 ModernaTX, Inc. $358,060.50 12/14/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260313
Principal investigator 1 ModernaTX, Inc. $363,622.50 12/14/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260319
Principal investigator 1 ModernaTX, Inc. $86,718.80 12/09/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260165
Principal investigator 1 ModernaTX, Inc. $104,441.40 12/09/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260295
Principal investigator 1 ModernaTX, Inc. $177,498.00 12/09/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260301
Principal investigator 1 ModernaTX, Inc. $188,476.20 12/09/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260307
Principal investigator 1 ABBVIE INC. $25.00 12/08/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND
A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohnx27s Disease No dispute reported 06/30/2026 890369477
Principal investigator 1 Janssen Pharmaceuticals, Inc $14,498.00 12/05/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214987
Principal investigator 1 Janssen Pharmaceuticals, Inc $50.00 12/02/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214971
Principal investigator 1 ModernaTX, Inc. $166,558.28 12/02/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260159
Principal investigator 1 ModernaTX, Inc. $227,519.55 12/01/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260289
Principal investigator 1 ModernaTX, Inc. $21,898.69 11/25/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963678525
Principal investigator 1 ModernaTX, Inc. $5,840.00 11/25/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963678551
Principal investigator 1 ModernaTX, Inc. $9,900.00 11/25/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963678555
Principal investigator 1 ModernaTX, Inc. $160.00 11/22/2022 Non-covered Recipient Entity
FAMILY PRACTICE OF WEST VOLUSIA PA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 963295013
Principal investigator 1 Janssen Research & Development, LLC $3,856.00 11/21/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 885221339
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/21/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885248075
Principal investigator 1 Janssen Research & Development, LLC $11,054.95 11/21/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885248077
Principal investigator 1 Janssen Research & Development, LLC $8,622.00 11/18/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221295
Principal investigator 1 Janssen Research & Development, LLC $790.00 11/18/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221307
Principal investigator 1 AstraZeneca UK Limited $7,000.00 11/17/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH LLC
A Phase I Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of MEDI8367 administered as Single Ascending Doses in Healthy Subjects, and as a Single Dose in Healthy Subjects of Japanese-descent and in Subjects with Chronic Kidney Disease No dispute reported 06/30/2026 914593477
Principal investigator 1 Eli Lilly and Company $1,208.00 11/17/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A MASTER PROTOCOL FOR RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIALS OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF CHRONIC PAIN No dispute reported 06/30/2026 917845899
Principal investigator 1 Eli Lilly and Company $1,208.00 11/17/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A MASTER PROTOCOL FOR RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIALS OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF CHRONIC PAIN No dispute reported 06/30/2026 917846759
Principal investigator 1 Janssen Pharmaceuticals, Inc $2,188.00 11/16/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214967
Principal investigator 1 ModernaTX, Inc. $19,600.00 11/16/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963678545
Principal investigator 1 ModernaTX, Inc. $200.00 11/16/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963678547
Principal investigator 1 ModernaTX, Inc. $350.00 11/16/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963678549
Principal investigator 1 ModernaTX, Inc. $4,200.00 11/16/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963678553
Principal investigator 1 Janssen Research & Development, LLC $606.84 11/15/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 885221331
Principal investigator 1 Merck Sharp & Dohme LLC $8,625.00 11/14/2022 Non-covered Recipient Entity
SANDHILL RESEARCH LLC
A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older No dispute reported 06/30/2026 940395377
Principal investigator 1 ModernaTX, Inc. $5,000.00 11/14/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963678539
Principal investigator 1 ModernaTX, Inc. $750.00 11/14/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963678541
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,000.00 11/10/2022 Non-covered Recipient Entity
ACCEL CLINICAL
An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination with Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 953500253
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,000.00 11/10/2022 Non-covered Recipient Entity
ACCEL CLINICAL
An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination with Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 953500259
Principal investigator 1 Eli Lilly and Company $410.00 11/09/2022 Non-covered Recipient Entity
MERIDIEN RESEARCH
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 917827119
Principal investigator 1 ModernaTX, Inc. $55,836.00 11/09/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963678527
Principal investigator 1 ModernaTX, Inc. $5,961.60 11/09/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963678529
Principal investigator 1 ModernaTX, Inc. $93,798.00 11/09/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963678531
Principal investigator 1 ModernaTX, Inc. $118,197.90 11/09/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963678533
Principal investigator 1 ModernaTX, Inc. $11,383.20 11/09/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963678535
Principal investigator 1 ModernaTX, Inc. $10,297.80 11/09/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963678537
Principal investigator 1 ModernaTX, Inc. $13,935.00 11/09/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963678543
Principal investigator 1 Janssen Research & Development, LLC $158.00 11/07/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221311
Principal investigator 1 Janssen Pharmaceuticals, Inc $50.00 11/02/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214975
Principal investigator 1 Janssen Research & Development, LLC $947.90 10/31/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65Years No dispute reported 06/30/2026 885248031
Principal investigator 1 ModernaTX, Inc. $123,508.60 10/28/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260095
Principal investigator 1 Janssen Research & Development, LLC $1,797.50 10/27/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885248071
Principal investigator 1 Janssen Pharmaceuticals, Inc $4,965.00 10/26/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214959
Principal investigator 1 Janssen Research & Development, LLC $4,800.00 10/26/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221303
Principal investigator 1 Janssen Research & Development, LLC $9,981.00 10/26/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221315
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 10/25/2022 Non-covered Recipient Entity
UNIVERSITY OF CLINICAL DELAND LLC
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 944036589
Principal investigator 1 Janssen Research & Development, LLC $1,946.00 10/21/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221299
Principal investigator 1 ModernaTX, Inc. $1,017.02 10/19/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260089
Principal investigator 1 Janssen Research & Development, LLC $500.00 10/17/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221287
Principal investigator 1 Janssen Research & Development, LLC $50.00 10/17/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65Years No dispute reported 06/30/2026 885248037
Principal investigator 1 Janssen Pharmaceuticals, Inc $50.00 10/14/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214963
Principal investigator 1 ModernaTX, Inc. $1,975.05 10/14/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260083
Principal investigator 1 ModernaTX, Inc. $54,758.70 10/14/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260113
Principal investigator 1 Merck Sharp & Dohme LLC $21,450.00 10/12/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT
A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age No dispute reported 06/30/2026 940394934
Principal investigator 1 ModernaTX, Inc. $66,133.80 10/12/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260101
Principal investigator 1 ModernaTX, Inc. $8,135.10 10/12/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260107
Principal investigator 1 Janssen Research & Development, LLC $25.00 10/10/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65Years No dispute reported 06/30/2026 885248033
Principal investigator 1 Janssen Research & Development, LLC $30.00 10/10/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65Years No dispute reported 06/30/2026 885248035
Principal investigator 1 Janssen Pharmaceuticals, Inc $12,753.00 10/07/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214991
Principal investigator 1 Janssen Research & Development, LLC $50.00 10/07/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885248073
Principal investigator 1 ModernaTX, Inc. $148.50 10/07/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260119
Principal investigator 1 ModernaTX, Inc. $350.00 10/07/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260125
Principal investigator 1 ModernaTX, Inc. $347,660.10 10/07/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260131
Principal investigator 1 ModernaTX, Inc. $134,291.25 10/07/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260137
Principal investigator 1 ModernaTX, Inc. $101.25 10/07/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260143
Principal investigator 1 Janssen Research & Development, LLC $2,843.70 10/06/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65Years No dispute reported 06/30/2026 885248039
Principal investigator 1 ModernaTX, Inc. $8,605.58 10/05/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963260077
Principal investigator 1 ModernaTX, Inc. $80.00 10/04/2022 Non-covered Recipient Entity
FAMILY PRACTICE OF WEST VOLUSIA PA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 963295019
Principal investigator 1 Janssen Research & Development, LLC $898.75 09/29/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885248067
Principal investigator 1 PFIZER INC. $1,173.15 09/28/2022 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949788965
Principal investigator 1 Eli Lilly and Company $440.00 09/27/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 917836999
Principal investigator 1 Janssen Research & Development, LLC $898.75 09/26/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885248065
Principal investigator 1 ModernaTX, Inc. $195.75 09/23/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259291
Principal investigator 1 ModernaTX, Inc. $167.50 09/23/2022 Non-covered Recipient Entity
FAMILY PRACTICE OF WEST VOLUSIA PA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 963294995
Principal investigator 1 Janssen Research & Development, LLC $2,512.00 09/22/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 885221243
Principal investigator 1 PFIZER INC. $201,914.11 09/22/2022 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949788935
Principal investigator 1 Janssen Research & Development, LLC $260.00 09/19/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885248063
Principal investigator 1 Janssen Research & Development, LLC $118.00 09/16/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 885221239
Principal investigator 1 ModernaTX, Inc. $654.75 09/16/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259383
Principal investigator 1 ModernaTX, Inc. $263.25 09/14/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259309
Principal investigator 1 ModernaTX, Inc. $1,700.00 09/14/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259487
Principal investigator 1 ModernaTX, Inc. $3,700.00 09/14/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259533
Principal investigator 1 ModernaTX, Inc. $16,259.40 09/14/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259821
Principal investigator 1 Novo Nordisk AS $110.00 09/12/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897186471
Principal investigator 1 ModernaTX, Inc. $100.00 09/09/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259269
Principal investigator 1 ModernaTX, Inc. $700.00 09/09/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259395
Principal investigator 1 ModernaTX, Inc. $42,632.87 09/09/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259933
Principal investigator 1 ModernaTX, Inc. $80.00 09/08/2022 Non-covered Recipient Entity
FAMILY PRACTICE OF WEST VOLUSIA PA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 963295001
Principal investigator 1 ModernaTX, Inc. $282.14 09/07/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259315
Principal investigator 1 ModernaTX, Inc. $500.00 09/07/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259349
Principal investigator 1 ModernaTX, Inc. $506.25 09/07/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259355
Principal investigator 1 ModernaTX, Inc. $3,300.00 09/07/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259527
Principal investigator 1 ModernaTX, Inc. $8,950.50 09/07/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259625
Principal investigator 1 Janssen Research & Development, LLC $130.00 09/02/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885248069
Principal investigator 1 Janssen Research & Development, LLC $1,797.50 08/29/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885248057
Principal investigator 1 Janssen Pharmaceuticals, Inc $17,336.00 08/26/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214951
Principal investigator 1 ModernaTX, Inc. $1,219.05 08/26/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259435
Principal investigator 1 Janssen Pharmaceuticals, Inc $1,185.00 08/24/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214947
Principal investigator 1 ModernaTX, Inc. $434.99 08/24/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259331
Principal investigator 1 ModernaTX, Inc. $1,100.00 08/24/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259429
Principal investigator 1 ModernaTX, Inc. $1,545.38 08/24/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259475
Principal investigator 1 ModernaTX, Inc. $10,157.40 08/24/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259665
Principal investigator 1 ModernaTX, Inc. $26,315.55 08/24/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259879
Principal investigator 1 ModernaTX, Inc. $26,554.50 08/24/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259885
Principal investigator 1 Novo Nordisk AS $180.64 08/24/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897184651
Principal investigator 1 Novo Nordisk AS $75.00 08/24/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897236449
Principal investigator 1 Janssen Research & Development, LLC $16,670.31 08/22/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885248059
Principal investigator 1 ModernaTX, Inc. $50.00 08/22/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259251
Principal investigator 1 ModernaTX, Inc. $100.00 08/22/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259263
Principal investigator 1 ModernaTX, Inc. $500.00 08/22/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259343
Principal investigator 1 ModernaTX, Inc. $700.00 08/22/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259389
Principal investigator 1 ModernaTX, Inc. $1,500.00 08/22/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259457
Principal investigator 1 ModernaTX, Inc. $4,288.63 08/22/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259555
Principal investigator 1 ModernaTX, Inc. $6,600.00 08/22/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259613
Principal investigator 1 ModernaTX, Inc. $19,609.43 08/22/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259849
Principal investigator 1 Janssen Pharmaceuticals, Inc $640.00 08/19/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214943
Principal investigator 1 Janssen Research & Development, LLC $2,897.00 08/19/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221235
Principal investigator 1 Janssen Research & Development, LLC $16,363.00 08/19/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221259
Principal investigator 1 ModernaTX, Inc. $100.00 08/19/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259257
Principal investigator 1 ModernaTX, Inc. $486.00 08/19/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259337
Principal investigator 1 ModernaTX, Inc. $20,058.30 08/19/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259855
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $234.00 08/18/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ? 6 to <18 Years of Age No dispute reported 06/30/2026 933398489
Principal investigator 1 Janssen Research & Development, LLC $16,670.31 08/18/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885248061
Principal investigator 1 Emergent BioSolutions Inc. $155.00 08/17/2022 Non-covered Recipient Entity
University Clinical Research-Deland, LLC d/b/a Accel Research Sites
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 927087365
Principal investigator 1 Janssen Pharmaceuticals, Inc $50.00 08/17/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214935
Principal investigator 1 PFIZER INC. $31,854.11 08/17/2022 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949803827
Principal investigator 1 Janssen Pharmaceuticals, Inc $222.00 08/15/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214955
Principal investigator 1 ModernaTX, Inc. $121.50 08/15/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259273
Principal investigator 1 ModernaTX, Inc. $202.50 08/15/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259303
Principal investigator 1 ModernaTX, Inc. $20,078.82 08/15/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259861
Principal investigator 1 ModernaTX, Inc. $104,934.15 08/15/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259961
Principal investigator 1 ModernaTX, Inc. $1,367.55 08/12/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259445
Principal investigator 1 ABBVIE INC. $1,064.70 08/11/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND
A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohnx27s Disease No dispute reported 06/30/2026 890367397
Principal investigator 1 ABBVIE INC. $550.00 08/10/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND
A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohnx27s Disease No dispute reported 06/30/2026 890367399
Principal investigator 1 ABBVIE INC. $50.00 08/10/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND
A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohnx27s Disease No dispute reported 06/30/2026 890367401
Principal investigator 1 Emergent BioSolutions Inc. $709.47 08/10/2022 Non-covered Recipient Entity
University Clinical Research-Deland, LLC d/b/a Accel Research Sites
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 927087809
Principal investigator 1 Emergent BioSolutions Inc. $177,637.00 08/10/2022 Non-covered Recipient Entity
University Clinical Research-Deland, LLC d/b/a Accel Research Sites
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 927087829
Principal investigator 1 ModernaTX, Inc. $5,000.00 08/10/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259573
Principal investigator 1 ModernaTX, Inc. $5,100.00 08/10/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259579
Principal investigator 1 Emergent BioSolutions Inc. $10,837.50 08/03/2022 Non-covered Recipient Entity
University Clinical Research-Deland, LLC d/b/a Accel Research Sites
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 927087677
Principal investigator 1 Janssen Pharmaceuticals, Inc $125.00 08/03/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214939
Principal investigator 1 PFIZER INC. $6,809.48 08/03/2022 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949804075
Principal investigator 1 Janssen Research & Development, LLC $25,317.50 07/29/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885248055
Principal investigator 1 PFIZER INC. $3,479.65 07/28/2022 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949808543
Recipient Eli Lilly and Company $194.00 07/27/2022 Covered Recipient Physician RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 917809503
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 07/25/2022 Non-covered Recipient Entity
UNIVERSITY OF CLINICAL DELAND LLC
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 944036597
Principal investigator 1 Janssen Pharmaceuticals, Inc $30,523.00 07/22/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214931
Principal investigator 1 Janssen Research & Development, LLC $7,652.00 07/22/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221231
Principal investigator 1 Janssen Research & Development, LLC $13,382.00 07/22/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221255
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897011391
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897011395
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897011400
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897011404
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897047015
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897047019
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897047023
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897066395
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897066398
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897066401
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897066405
Principal investigator 1 Novo Nordisk AS $36.00 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897066437
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897066441
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897066929
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897086381
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897086385
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897086389
Principal investigator 1 Novo Nordisk AS $9.00 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897086717
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897108975
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897109099
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897109107
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897109111
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897109113
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897109117
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897109121
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897109125
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897118837
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897119129
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897119133
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897119137
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897119141
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897142891
Principal investigator 1 Novo Nordisk AS $9.00 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897143935
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897143966
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897143971
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897143975
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897144049
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897144053
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897144057
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897144061
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897144077
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897144081
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897144085
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897144089
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897175763
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897175767
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897175771
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897175780
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897175785
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897176601
Principal investigator 1 Novo Nordisk AS $5.70 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897176679
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897176683
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897176687
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897176691
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897177549
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897177553
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897177853
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897184563
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897184566
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897184570
Principal investigator 1 Novo Nordisk AS $6.50 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897184574
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897184647
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897184655
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897186933
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897186995
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897186997
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897187003
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897187007
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897187011
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897187015
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897187019
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897187023
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897187027
Principal investigator 1 Novo Nordisk AS $60.00 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897187031
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897187034
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897187037
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897187173
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897188671
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897221103
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897221347
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897221351
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897221359
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897221363
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897221367
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897221371
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897235189
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897236351
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897236355
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897236359
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897236363
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897236367
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897236371
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897236372
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897236376
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897236380
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897236384
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897236388
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897236393
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897236395
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897236399
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897236404
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897236408
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897236455
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897236459
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 897236511
Principal investigator 1 PFIZER INC. $4,010.53 07/21/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 949786845
Principal investigator 1 PFIZER INC. $870.00 07/21/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 949786871
Principal investigator 1 PFIZER INC. $1,000.00 07/21/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 949787099
Principal investigator 1 ModernaTX, Inc. $1,028.57 07/15/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259417
Principal investigator 1 ModernaTX, Inc. $1,757.03 07/15/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259493
Principal investigator 1 ModernaTX, Inc. $2,057.13 07/15/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259497
Principal investigator 1 ModernaTX, Inc. $2,059.70 07/15/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259503
Principal investigator 1 ModernaTX, Inc. $14,956.52 07/15/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259809
Principal investigator 1 Emergent BioSolutions Inc. $2,963.78 07/13/2022 Non-covered Recipient Entity
University Clinical Research-Deland, LLC d/b/a Accel Research Sites
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 927087937
Principal investigator 1 Janssen Research & Development, LLC $599.00 07/11/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221251
Principal investigator 1 Janssen Pharmaceuticals, Inc $3,995.00 07/08/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214927
Principal investigator 1 Janssen Research & Development, LLC $125.00 07/08/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65Years No dispute reported 06/30/2026 885248027
Principal investigator 1 Janssen Research & Development, LLC $3,550.12 07/08/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65Years No dispute reported 06/30/2026 885248029
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $500.00 07/06/2022 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH, LLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936714165
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $5,000.00 07/06/2022 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH, LLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936714175
Principal investigator 1 Janssen Research & Development, LLC $500.00 07/06/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 885221247
Principal investigator 1 Janssen Pharmaceuticals, Inc $128.00 07/05/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214923
Principal investigator 1 PFIZER INC. $79,548.08 06/30/2022 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949812599
Principal investigator 1 Horizon Therapeutics plc $2,500.00 06/29/2022 Non-covered Recipient Entity
AVAIL RESEARCH
A MULTICENTER, EFFICACY AND SAFETY STUDY OF METHOTREXATE TO INCREASE RESPONSE RATES IN PATIENTS WITH UNCONTROLLED GOUT RECEIVING KRYSTEXXA? (PEGLOTICASE) (MIRROR [OL]) No dispute reported 06/30/2026 937593683
Principal investigator 1 ModernaTX, Inc. $846.45 06/29/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259405
Principal investigator 1 ModernaTX, Inc. $1,028.57 06/29/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259411
Principal investigator 1 ModernaTX, Inc. $1,241.46 06/29/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259441
Principal investigator 1 ModernaTX, Inc. $1,544.13 06/29/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259463
Principal investigator 1 ModernaTX, Inc. $1,544.13 06/29/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259469
Principal investigator 1 ModernaTX, Inc. $3,814.16 06/29/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259543
Principal investigator 1 ModernaTX, Inc. $4,329.72 06/29/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259561
Principal investigator 1 ModernaTX, Inc. $9,223.74 06/29/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259631
Principal investigator 1 Janssen Research & Development, LLC $193.00 06/24/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885248053
Principal investigator 1 Janssen Research & Development, LLC $12,850.00 06/22/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221173
Principal investigator 1 Janssen Research & Development, LLC $12,850.00 06/22/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221227
Principal investigator 1 Janssen Pharmaceuticals, Inc $14,921.00 06/20/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214919
Principal investigator 1 Janssen Research & Development, LLC $15,702.00 06/17/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221140
Principal investigator 1 Janssen Research & Development, LLC $4,600.00 06/17/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221169
Principal investigator 1 Janssen Research & Development, LLC $15,702.00 06/17/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221199
Principal investigator 1 Janssen Research & Development, LLC $4,600.00 06/17/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221223
Principal investigator 1 ModernaTX, Inc. $29,625.75 06/08/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259897
Principal investigator 1 Janssen Research & Development, LLC $1,840.00 06/06/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65Years No dispute reported 06/30/2026 885248025
Principal investigator 1 ModernaTX, Inc. $515.57 06/03/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259371
Principal investigator 1 ModernaTX, Inc. $1,031.13 06/03/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259423
Principal investigator 1 ModernaTX, Inc. $12,555.68 06/03/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259689
Principal investigator 1 ModernaTX, Inc. $14,443.52 06/03/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259705
Principal investigator 1 ModernaTX, Inc. $14,953.95 06/03/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259803
Principal investigator 1 ModernaTX, Inc. $18,591.12 06/03/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259843
Recipient Eli Lilly and Company $268.00 06/02/2022 Covered Recipient Physician A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 917808957
Principal investigator 1 Janssen Pharmaceuticals, Inc $1,896.00 06/01/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214915
Principal investigator 1 Janssen Research & Development, LLC $8,694.00 05/30/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65Years No dispute reported 06/30/2026 885248023
Principal investigator 1 Emergent BioSolutions Inc. $75.00 05/25/2022 Non-covered Recipient Entity
University Clinical Research-Deland, LLC d/b/a Accel Research Sites
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 927087375
Principal investigator 1 PFIZER INC. $30,126.73 05/25/2022 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949744339
Principal investigator 1 Janssen Research & Development, LLC $8,700.00 05/23/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885248047
Principal investigator 1 Janssen Research & Development, LLC $500.00 05/23/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885248049
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 05/23/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885248051
Principal investigator 1 Janssen Pharmaceuticals, Inc $19,861.00 05/20/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214911
Principal investigator 1 Janssen Research & Development, LLC $5,284.00 05/20/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221135
Principal investigator 1 Janssen Research & Development, LLC $18,884.00 05/20/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221165
Principal investigator 1 Janssen Research & Development, LLC $5,284.00 05/20/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221195
Principal investigator 1 Janssen Research & Development, LLC $18,884.00 05/20/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221219
Principal investigator 1 Janssen Research & Development, LLC $1,016.00 05/18/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221131
Principal investigator 1 Janssen Research & Development, LLC $1,016.00 05/18/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221191
Principal investigator 1 Astellas Pharma Inc $1,722.50 05/16/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function No dispute reported 06/30/2026 903652491
Principal investigator 1 Janssen Research & Development, LLC $800.00 05/13/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221161
Principal investigator 1 Janssen Research & Development, LLC $800.00 05/13/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221215
Principal investigator 1 ABBVIE INC. $1,500.00 05/12/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND
A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohnx27s Disease No dispute reported 06/30/2026 890363037
Principal investigator 1 Astellas Pharma Inc $15,502.50 05/12/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function No dispute reported 06/30/2026 903652473
Principal investigator 1 Janssen Research & Development, LLC $58,329.00 05/11/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221127
Principal investigator 1 Janssen Research & Development, LLC $58,329.00 05/11/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221187
Principal investigator 1 ModernaTX, Inc. $57,591.00 05/11/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259943
Principal investigator 1 Janssen Research & Development, LLC $2,787.20 05/06/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65Years No dispute reported 06/30/2026 885248021
Principal investigator 1 Janssen Pharmaceuticals, Inc $9,974.00 05/04/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214907
Principal investigator 1 Janssen Research & Development, LLC $250.00 05/04/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221123
Principal investigator 1 Janssen Research & Development, LLC $64,833.00 05/04/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221157
Principal investigator 1 Janssen Research & Development, LLC $250.00 05/04/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221183
Principal investigator 1 Janssen Research & Development, LLC $64,833.00 05/04/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221211
Principal investigator 1 ModernaTX, Inc. $423.23 05/04/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259325
Principal investigator 1 ModernaTX, Inc. $6,176.52 05/04/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259595
Principal investigator 1 ModernaTX, Inc. $9,264.78 05/04/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259637
Principal investigator 1 ModernaTX, Inc. $29,270.70 05/04/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259891
Principal investigator 1 PFIZER INC. $11,431.29 05/03/2022 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949744345
Principal investigator 1 ModernaTX, Inc. $1,400.00 05/02/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259451
Principal investigator 1 Janssen Research & Development, LLC $500.00 04/29/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65Years No dispute reported 06/30/2026 885248017
Principal investigator 1 AstraZeneca UK Limited $2,104.00 04/28/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH LLC
A single dose, non-randomized, open-label, parallel group study to assess the pharmacokinetics, safety and tolerability of AZD9977 in participants with renal impairment No dispute reported 06/30/2026 914590303
Principal investigator 1 Astellas Pharma Inc $150.00 04/25/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function No dispute reported 06/30/2026 903652475
Principal investigator 1 Astellas Pharma Inc $750.00 04/25/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function No dispute reported 06/30/2026 903652479
Principal investigator 1 Astellas Pharma Inc $1,000.00 04/25/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function No dispute reported 06/30/2026 903652481
Principal investigator 1 Janssen Pharmaceuticals, Inc $9,999.00 04/25/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214903
Principal investigator 1 Janssen Research & Development, LLC $5,112.00 04/22/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221119
Principal investigator 1 Janssen Research & Development, LLC $32,726.00 04/22/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221153
Principal investigator 1 Janssen Research & Development, LLC $5,112.00 04/22/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221179
Principal investigator 1 Janssen Research & Development, LLC $32,726.00 04/22/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221207
Principal investigator 1 ModernaTX, Inc. $50.00 04/20/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259245
Principal investigator 1 ModernaTX, Inc. $200.00 04/20/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259297
Principal investigator 1 ModernaTX, Inc. $515.57 04/20/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259359
Principal investigator 1 ModernaTX, Inc. $515.57 04/20/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259365
Principal investigator 1 ModernaTX, Inc. $1,546.70 04/20/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259481
Principal investigator 1 ModernaTX, Inc. $2,272.59 04/20/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259509
Principal investigator 1 ModernaTX, Inc. $15,569.55 04/20/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259815
Principal investigator 1 ModernaTX, Inc. $25,891.11 04/20/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259873
Principal investigator 1 ModernaTX, Inc. $33,547.64 04/20/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259921
Principal investigator 1 PFIZER INC. $2,423.27 04/20/2022 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949821613
Principal investigator 1 PFIZER INC. $2,423.27 04/19/2022 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949821611
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,500.00 04/15/2022 Non-covered Recipient Entity
ACCEL CLINICAL
An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination with Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 953484857
Principal investigator 1 Deciphera Pharmaceuticals Inc. $6,000.00 04/15/2022 Non-covered Recipient Entity
ACCEL CLINICAL
An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination with Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 953484863
Principal investigator 1 ModernaTX, Inc. $16,635.31 04/15/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259827
Principal investigator 1 Janssen Research & Development, LLC $3,267.00 04/12/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 885221145
Principal investigator 1 ModernaTX, Inc. $141.08 04/08/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259285
Principal investigator 1 ModernaTX, Inc. $9,970.16 04/08/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259659
Principal investigator 1 ModernaTX, Inc. $10,530.61 04/08/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259677
Principal investigator 1 ModernaTX, Inc. $22,133.39 04/08/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259867
Principal investigator 1 ModernaTX, Inc. $30,364.47 04/08/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259909
Principal investigator 1 ModernaTX, Inc. $33,439.91 04/08/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259915
Principal investigator 1 Janssen Research & Development, LLC $4,066.80 04/07/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65Years No dispute reported 06/30/2026 885248019
Principal investigator 1 Janssen Pharmaceuticals, Inc $133.00 04/06/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214899
Principal investigator 1 Janssen Research & Development, LLC $1,825.00 04/06/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221115
Principal investigator 1 Janssen Research & Development, LLC $600.00 04/06/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221149
Principal investigator 1 Janssen Research & Development, LLC $1,825.00 04/06/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221175
Principal investigator 1 Janssen Research & Development, LLC $600.00 04/06/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221203
Principal investigator 1 ModernaTX, Inc. $2,482.92 04/06/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259515
Principal investigator 1 ModernaTX, Inc. $2,482.92 04/06/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259521
Principal investigator 1 ModernaTX, Inc. $3,724.38 04/06/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259539
Principal investigator 1 ModernaTX, Inc. $4,027.05 04/06/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259549
Principal investigator 1 ModernaTX, Inc. $4,965.84 04/06/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259567
Principal investigator 1 ModernaTX, Inc. $5,994.41 04/06/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259589
Principal investigator 1 ModernaTX, Inc. $6,207.30 04/06/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259601
Principal investigator 1 ModernaTX, Inc. $9,505.89 04/06/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259643
Principal investigator 1 ModernaTX, Inc. $9,718.79 04/06/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259647
Principal investigator 1 ModernaTX, Inc. $9,931.68 04/06/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259653
Principal investigator 1 ModernaTX, Inc. $10,874.32 04/06/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259683
Principal investigator 1 ModernaTX, Inc. $13,656.06 04/06/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259695
Principal investigator 1 ModernaTX, Inc. $13,966.43 04/06/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259699
Principal investigator 1 ModernaTX, Inc. $16,741.76 04/06/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259831
Principal investigator 1 ModernaTX, Inc. $17,380.44 04/06/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259837
Principal investigator 1 ModernaTX, Inc. $49,076.15 04/06/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259937
Principal investigator 1 PFIZER INC. $750.00 03/31/2022 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949822427
Principal investigator 1 PFIZER INC. $1,000.00 03/31/2022 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949822429
Principal investigator 1 PFIZER INC. $750.00 03/31/2022 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949822431
Principal investigator 1 ModernaTX, Inc. $600.00 03/30/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259377
Principal investigator 1 PFIZER INC. $3,793.52 03/29/2022 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949825067
Principal investigator 1 Janssen Pharmaceuticals, Inc $5,275.00 03/28/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214895
Principal investigator 1 Janssen Research & Development, LLC $8,610.00 03/28/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221111
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 03/28/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65Years No dispute reported 06/30/2026 885248015
Principal investigator 1 Janssen Research & Development, LLC $1,327.00 03/25/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221079
Principal investigator 1 Janssen Research & Development, LLC $1,327.00 03/25/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221279
Principal investigator 1 Janssen Research & Development, LLC $500.00 03/25/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65Years No dispute reported 06/30/2026 885248013
Principal investigator 1 PFIZER INC. $118.75 03/24/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 949808731
Principal investigator 1 ABBVIE INC. $25.00 03/23/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND
A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohnx27s Disease No dispute reported 06/30/2026 890361197
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 03/23/2022 Non-covered Recipient Entity
University Clinical Research - Deland, LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910129047
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 03/23/2022 Non-covered Recipient Entity
University Clinical Research - Deland, LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910129049
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,000.00 03/23/2022 Non-covered Recipient Entity
University Clinical Research - Deland, LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910129051
Principal investigator 1 Alnylam Pharmaceuticals Inc. $819.00 03/23/2022 Non-covered Recipient Entity
University Clinical Research - Deland, LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910129053
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 03/23/2022 Non-covered Recipient Entity
University Clinical Research - Deland, LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910129055
Principal investigator 1 Emergent BioSolutions Inc. $500.00 03/23/2022 Non-covered Recipient Entity
University Clinical Research-Deland, LLC d/b/a Accel Research Sites
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 927087919
Principal investigator 1 Janssen Research & Development, LLC $67,682.00 03/23/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221076
Principal investigator 1 Janssen Research & Development, LLC $63,657.00 03/23/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221107
Principal investigator 1 Janssen Research & Development, LLC $67,682.00 03/23/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221275
Principal investigator 1 PFIZER INC. $7,612.01 03/22/2022 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949825107
Principal investigator 1 Janssen Pharmaceuticals, Inc $8,216.00 03/18/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214891
Principal investigator 1 PFIZER INC. $500.00 03/16/2022 Non-covered Recipient Entity
University Clinical ResearchDeLand LLC
A 16WEEK PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN OR DIET AND EXERCISE No dispute reported 06/30/2026 949825111
Principal investigator 1 Astellas Pharma Inc $2,693.80 03/14/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function No dispute reported 06/30/2026 903652201
Principal investigator 1 Astellas Pharma Inc $306.20 03/14/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function No dispute reported 06/30/2026 903652203
Principal investigator 1 Astellas Pharma Inc $2,133.67 03/14/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function No dispute reported 06/30/2026 903652207
Principal investigator 1 Janssen Research & Development, LLC $200.00 03/11/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221103
Principal investigator 1 Janssen Research & Development, LLC $4,577.30 03/10/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65Years No dispute reported 06/30/2026 885248011
Principal investigator 1 Eli Lilly and Company $74,566.00 03/09/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 917846773
Principal investigator 1 Janssen Pharmaceuticals, Inc $465.00 03/09/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214887
Principal investigator 1 ModernaTX, Inc. $141.08 03/09/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259279
Principal investigator 1 ModernaTX, Inc. $282.15 03/09/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259320
Principal investigator 1 ModernaTX, Inc. $801.56 03/09/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259401
Principal investigator 1 ModernaTX, Inc. $5,890.52 03/09/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259583
Principal investigator 1 Janssen Research & Development, LLC $25.00 03/04/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221101
Principal investigator 1 PFIZER INC. $1,164.94 03/03/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 949808733
Principal investigator 1 Alnylam Pharmaceuticals Inc. $400.00 03/02/2022 Non-covered Recipient Entity
University Clinical Research - Deland, LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910129045
Principal investigator 1 Emergent BioSolutions Inc. $2,000.00 03/02/2022 Non-covered Recipient Entity
University Clinical Research-Deland, LLC d/b/a Accel Research Sites
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 927087933
Principal investigator 1 Janssen Pharmaceuticals, Inc $384.00 03/02/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214883
Principal investigator 1 Janssen Research & Development, LLC $600.00 03/02/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221072
Principal investigator 1 Janssen Research & Development, LLC $13,224.00 03/02/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221095
Principal investigator 1 Janssen Research & Development, LLC $600.00 03/02/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221271
Principal investigator 1 PFIZER INC. $41,059.21 03/01/2022 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949825109
Principal investigator 1 Eli Lilly and Company $4,772.00 02/23/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A MULTIPLE-DOSE, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3372993 IN PARTICIPANTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917845891
Principal investigator 1 Janssen Research & Development, LLC $19,542.00 02/23/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221091
Principal investigator 1 Janssen Pharmaceuticals, Inc $19,416.00 02/16/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214879
Principal investigator 1 ModernaTX, Inc. $29,997.00 02/16/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259903
Principal investigator 1 ModernaTX, Inc. $57,627.45 02/16/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259949
Principal investigator 1 Eli Lilly and Company $138,287.00 02/14/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A MULTIPLE-DOSE, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3372993 IN PARTICIPANTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917845883
Principal investigator 1 Janssen Pharmaceuticals, Inc $100.00 02/11/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214875
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 02/08/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 885221319
Principal investigator 1 Janssen Research & Development, LLC $500.00 02/08/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 885221323
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 02/08/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 885221327
Principal investigator 1 Janssen Research & Development, LLC $200.00 02/04/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221069
Principal investigator 1 Janssen Research & Development, LLC $200.00 02/04/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221267
Principal investigator 1 PFIZER INC. $4,107.56 02/03/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 949807507
Principal investigator 1 PFIZER INC. $28,884.78 02/01/2022 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949826855
Principal investigator 1 Janssen Research & Development, LLC $2,741.00 01/26/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221065
Principal investigator 1 Janssen Research & Development, LLC $8,879.00 01/26/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221088
Principal investigator 1 Janssen Research & Development, LLC $2,741.00 01/26/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885221263
Principal investigator 1 PFIZER INC. $150.00 01/25/2022 Non-covered Recipient Entity
AVAIL CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949821325
Principal investigator 1 PFIZER INC. $63,187.78 01/25/2022 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949828215
Principal investigator 1 Janssen Pharmaceuticals, Inc $30,085.00 01/21/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214871
Principal investigator 1 ModernaTX, Inc. $6,507.00 01/14/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259607
Principal investigator 1 ModernaTX, Inc. $8,672.40 01/14/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259619
Principal investigator 1 ModernaTX, Inc. $10,300.50 01/14/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259671
Principal investigator 1 ModernaTX, Inc. $63,957.60 01/14/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259955
Principal investigator 1 PFIZER INC. $3,635.55 01/12/2022 Non-covered Recipient Entity
University Clinical Research DeLand LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949828217
Principal investigator 1 Janssen Pharmaceuticals, Inc $25.00 01/07/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885214867
Principal investigator 1 Janssen Research & Development, LLC $20,550.00 01/07/2022 Non-covered Recipient Entity
Univ Clnc Rsrch - Deland, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885221084
Principal investigator 1 Eli Lilly and Company $768.00 01/05/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 917846891
Principal investigator 1 ModernaTX, Inc. $41,719.78 01/05/2022 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH D
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963259927